Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Learning and Neuroprotective Role Proffered for Glucagon-Derived Peptide
24 August 2003. In this week's Nature Medicine, researchers reveal that glucagon-like peptide-1 (GLP-1), a product of proglucagon processing, may have an important role in learning and neuroprotection.

The peptide, first found in intestinal L cells of the gut, is also expressed in the brain, along with its receptor (GLP-1R). This prompted principal investigator Colin Haile, Jefferson Medical College, Philadelphia, to investigate the role of GLP-1 in neurons. Working with an international group of collaborators, Haile and first author Matthew During looked for potential neurologic roles for the peptide. When they administered it to rats, the authors found that the animals performed better than controls in a variety of learning tasks. In the Morris water maze, for example, rats directly injected in the brain with 0.1 micrograms of GLP-1 traveled much shorter distances (about two meters on average) than untreated littermates (about 10 meters) in search of the hidden platform.

To further investigate the role of the peptide, During and colleagues used a strain of mice deficient in the peptide receptor (GLP-1R). These animals showed deficits in learning, as judged by their relative haste in re-exposing themselves to a negative stimulus-wild-type animals took on average three times as long before re-exposure. When During transfected the GLP-1R-negative mice with adeno-associated virus carrying the receptor, however, their responses improved. In a similar experiment, During induced overexpression of the receptor in the hippocampus of otherwise normal rats. These animals outperformed controls in a variety of tests including the water maze, where their traveling distance to the platform was half the norm.

The latter experiment suggests that GLP-1 may play a role in the hippocampus. Previous experiments have also indicated that the peptide may be neuroprotective (see Perry et al., 2002). To test this hypothesis, During and colleagues examined the effect of kainic acid on normal and GLP-1R negative mice-the acid is known to induce excitotoxic neuronal damage in the hippocampus. The authors found that the homozygous null mice succumbed to seizure much faster (after about 1,600 seconds) than did wild type animals (typically after 2,400 seconds). The results were statistically significant.

How the peptide works is uncertain, but as the receptor is coupled to multiple G-proteins, it could activate one or more signaling pathways. In support of this, the authors found that the first nine amino acids of the GLP-1 analog Ser(2) exendin-which also improves learning when administered intranasally to rats-leads to a significant increase in phosphorylation of MAP kinase in rat hippocampuses. MAP kinase may thus mediate the improvement in learning. During's experiments supports this, as Ser(2) exendin (1-9)-mediated learning improvements were blocked by PD98059, an inhibitor of the MAP kinase pathway. The authors conclude that "GLP-1R may be a promising target for therapeutic strategies directed towards neurodegenerative and cognitive disorders."-Tom Fagan.

Reference:
During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, Haile CN. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003 Sep;9(9):1173-1179. Epub 2003 Aug 17. Abstract

 
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad